Accellacare South London
Welcome,         Profile    Billing    Logout  
 3 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Smith, Jackie N
NCT02438306: CardiAMP™ Cell Therapy for Heart Failure Trial

Active, not recruiting
3
125
Canada, US
Autologous cell therapy, Sham
BioCardia, Inc.
Heart Failure, Systolic
12/24
12/26
RIVER, NCT05962151: Refractory Chronic Cough Improvement Via NAL ER

Active, not recruiting
2
60
Europe, Canada
Nalbuphine ER, Active, Placebo
Trevi Therapeutics
Refractory Chronic Cough
01/25
01/25
DisTinGuish, NCT04363801: A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Hourglass Oct 2023 - Mar 2024 : Q4'23/Q1'24 - Initial ORR data from DisTinGuish trial for 2L gastric cancer
Oct 2023 - Dec 2023: Initial data from part C of DisTinGuish trial in combination with tislelizumab for 1L gastric cancer
Checkmark Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Nov 2022 - Nov 2022: Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Checkmark ORR, PFS and OS data from DisTinGuish trial in combination with tislelizumab for gastroesophageal junction cancer or gastric cancer
More
Active, not recruiting
2
232
Europe, US, RoW
DKN-01 300mg, DKN-01 600mg, DKN-01 400mg, Tislelizumab 200mg, Tislelizumab 400mg, Oxaliplatin, Capecitabine 1000mg/ m2 BID, Xeloda, Leucovorin Calcium, Folinic acid, Fluorouracil
Leap Therapeutics, Inc., BeiGene
Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
06/25
12/25
NCT03943004: Trial of DFP-14927 in Advanced Solid Tumors

Recruiting
1
30
US
DFP-14927
Delta-Fly Pharma, Inc.
Solid Tumor, Cancer
09/24
12/24
Rahman, Nowshin
RIVER, NCT05962151: Refractory Chronic Cough Improvement Via NAL ER

Active, not recruiting
2
60
Europe, Canada
Nalbuphine ER, Active, Placebo
Trevi Therapeutics
Refractory Chronic Cough
01/25
01/25
Savill, Charlotte
RIVER, NCT05962151: Refractory Chronic Cough Improvement Via NAL ER

Active, not recruiting
2
60
Europe, Canada
Nalbuphine ER, Active, Placebo
Trevi Therapeutics
Refractory Chronic Cough
01/25
01/25

Download Options